摘要
目的：比较齐拉西酮与喹硫平治疗早期精神分裂症的疗效及不良反应。方法：96例符合CCMD-3的精神分裂症患者随机分为两组各48例，分别给予齐拉西酮和喹硫平治疗8周，采用阳性症状与阴性症状量表（PANSS）及不良反应量表（TESS）评定疗效和不良反应。结果：治疗8周后，齐拉西酮组的显效率为83．33％，有效率为95．83％；喹硫平组的显效率为81．25％，有效率93．75％。两组疗效无显著性差异（P〉0．05）。齐拉西酮组的不良反应发生率为20．83％，喹硫平组为22．92％，两组无显著性差异（P〉0．05），齐拉西酮组的泌乳素水平低于喹硫平组，有显著性差异（P〈0．05）。结论：齐拉西酮和利培酮对精神分裂症的总体疗效相当，但齐拉西酮对阴性症状的效果更好，齐拉西酮的不良反应与喹硫平相似，但齐拉西酮更适合女性患者。
Objective：To compare the efficacy and safety of Ziprasidone and Quetiapine in the treatment of schizophrenia. Methods：98 patients with schizophrenia were stochastic allocated to two groups treated with Ziprasidone and Quetiapine for 8 weeks. The Positive and Negative Syndrome Scale （PANSS） and Treatment Emergent Side Effect Scale were used to evaluate the efficacy and side effects. Results： The significant efficacy rates of Ziprasidone was 83.33% and the efficacy rates was 95.83% after 8 weeks, while that was 81.25% and 93.75% in Quetiapine group. There was no significant difference between the two groups （ P 〉 0.05）. The incidence rate of adverse effect was 20.83% in Ziprasidone group and that was 22.92% in Quetiapine group, and there was not a significant difference between them （P 〉 0.05 ）. The level of PRL in Ziprasidone was lower than that of Quetiapine. Conclusions： Ziprasidone is as effective and safe as Quetiapine for the treatment of schizophrenia, but Ziprasidone had a better effect for negative symptoms than Quetiapine. The side effects of Ziprasidone are similar to Quetiapine. However, Ziprasidone was more suitable for women patients.
出处
《中国民康医学》
2009年第11期1241-1242,共2页
Medical Journal of Chinese People’s Health
